Alzheimer’s Disease Diagnostics Market To Reach $15.92 Billion By 2030

Alzheimer’s Disease Diagnostics Market Growth & Trends

The global alzheimer’s disease diagnostics market size is expected to reach USD 15.92 billion by 2030, registering a CAGR of 11.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is driven by rising prevalence of Alzheimer’s disease (AD), growing use of biomarkers in disease diagnostics, growing adoption of personalized products, and increasing technological advancements in medical imaging are some of the factors which is expected to drive the demand for Alzheimer’s disease diagnostics. Increasing government investments and R&D studies is further propelling growth.

The global aging population with chronic conditions such as Alzheimer’s disease, which is the most common form of dementia, is another major factor driving the market for Alzheimer’s disease diagnostics. According to the WHO, Alzheimer’s disease causes 60–70% of all instances of dementia, making it the most common kind. According to the Alzheimer’s Association reports, an estimated 6.7 million Americans aged 65 and older were living with Alzheimer’s disease in 2023. This number is projected to nearly triple to 13.8 million people by 2060, and the studies project that the healthcare cost for AD patients in 2022 was around USD 321 billion in the U.S, itself.

The market trends are shifting towards the development of more accurate and non-invasive diagnostic tools. Recent advances in technology have led to the development of biomarkers, such as amyloid-beta and tau proteins, which can be detected in cerebrospinal fluid or blood samples. These biomarkers have shown promise in detecting Alzheimer’s disease in its early stages, allowing for earlier intervention and treatment. Additionally, advances in neuroimaging techniques, such as functional magnetic resonance imaging (fMRI) and positron emission tomography (PET), have improved the accuracy of Alzheimer’s disease diagnosis.

Recent examples of innovative diagnostic technologies for Alzheimer’s disease include the development of blood-based biomarkers, such as the p-tau217 test, which has shown high accuracy in detecting the disease. Another example is the use of digital biomarkers, such as cognitive assessments and wearable devices, to track cognitive decline and identify early signs of Alzheimer’s disease. Companies such as Biogen and Eisai are also investing in digital health technologies to support clinical trials and improve patient outcomes. Moreover, researchers are exploring the potential of machine learning and natural language processing to analyze speech patterns and identify early signs of cognitive decline. These advances in diagnostic technology are expected to revolutionize the field of Alzheimer’s disease diagnosis, enabling earlier intervention and more effective treatment strategies.

Presence of government funding programs aimed at reducing the burden of orthopedic diseases, by funding various clinical trials aimed at, is expected to have a positive impact on the market, In addition, governments are allocating substantial funds for research and development (R&D) in the field of Alzheimer’s diagnostics. This funding supports the development of new diagnostic technologies, such as advanced imaging techniques, biomarker assays, and cognitive assessment tools. Increased R&D investment accelerates the pace of innovation and helps bring new diagnostic solutions to the market

Some of the key players in the market are Quest Diagnostics, Labcorp, C2N Diagnostics, Fujirebio, Bristol Myers Squibb, Hoffmann-La Roche, and Quanterix. These players are involved in various strategic initiatives such as product launch and approval in order to cater to a global clientele. For instance, in April 2024, Quest Diagnostics announced its portfolio expansion by adding a new blood biomarker test for phosphorylated tau 217 (p-tau217). Companies further have been innovating in various blood-based biomarkers, cerebrospinal fluid tests, and genetic tests to provide a comprehensive offering in brain health.

 Request a free sample copy or view report summary: Alzheimer’s Disease Diagnostics Market Report

Alzheimer’s Disease Diagnostics Market Report Highlights

• Based on diagnostics technique, imaging techniques accounted for the largest revenue share in 2023. Such initiatives are expected to drive market growth. This high share is attributable to the urgent need for early and accurate detection of the disease. Advancements in imaging technologies such as Computed Tomography (CT), Positron Emission Tomography (PET), functional MRI (fMRI) have emerged as crucial tools for diagnosing and monitoring the disease.

• Based on type, diagnosis dominated the market and accounted for the largest share in 2023. The global market is expanding as the aging population rises, with more individuals at risk of developing Alzheimer’s disease. This has heightened the demand for early and accurate diagnostic tools, driving the market forward.

• Based on end use, academic and research institutes segment dominated the market with the largest market share in 2023. This is attributable to the increase in the research studies and clinical trials for neurological disorders over the last decade. Academic and research institutes are at the forefront of advanced research, clinical trials, and the development of innovative diagnostic techniques.

• North America dominated the global market due to the presence of a large number of major market players at the forefront of research into Alzheimer’s disease biomarkers, including cerebrospinal fluid analysis and blood-based biomarkers. These advancements are driving the development of more accurate and minimally invasive diagnostic tests.

• Asia Pacific region is expected to witness the fastest growth over the forecast period from 2024 to 2030, due to presence of manufacturers with innovative devices manufacturing capabilities coupled with accelerated diagnostic research capabilities.

Alzheimer’s Disease Diagnostics Market Segmentation

Grand View Research has segmented the global Alzheimer’s disease diagnostics market based on diagnostics technique, type, end-use, and region:

Alzheimer’s Disease Diagnostics By Diagnostics Technique Outlook (Revenue, USD Million, 2018 - 2030)

• Biomarkers

  • CSF Biomarkers

  • Blood-Based Biomarkers

• Imaging Techniques

• Genetic Testing

• Cognitive Assessment Tests

Alzheimer’s Disease Diagnostics Test Type Outlook (Revenue, USD Million, 2018 - 2030)

• Triage

• Diagnosis

• Screening

Alzheimer’s Disease Diagnostics End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Diagnostic Laboratories

• Academic and Research Institutes

Alzheimer’s Disease Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia-Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Argentina

• Middle East Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Alzheimer’s Disease Diagnostics Market

• Quest Diagnostics

• Labcorb

• C2N diagnostics

• FujireBio

• Bristol Myers Squibb

• Hoffmann-La Roche

• Quanterix

• Sysmex

• Lantheus

• Siemens Healthineers